Thomas Wehler

2.2k total citations
55 papers, 1.2k citations indexed

About

Thomas Wehler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Thomas Wehler has authored 55 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Thomas Wehler's work include Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Colorectal Cancer Treatments and Studies (9 papers). Thomas Wehler is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Colorectal Cancer Treatments and Studies (9 papers). Thomas Wehler collaborates with scholars based in Germany, United States and Spain. Thomas Wehler's co-authors include Kirsten Westesen, Massimo Busin, Nicolas Dickgreber, Jacob Westman, Rudolf M. Huber, Martin Schütz, Theo Pelzer, Petra Hoffknecht, Rainer Wiewrodt and Angela Märten and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Ophthalmology.

In The Last Decade

Thomas Wehler

49 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Wehler Germany	18	631	468	380	118	110	55	1.2k
Muhammad Furqan United States	20	814 1.3×	285 0.6×	800 2.1×	259 2.2×	86 0.8×	114	1.8k
Kathryn W. Woodburn United States	27	217 0.3×	1.1k 2.3×	467 1.2×	93 0.8×	172 1.6×	72	2.1k
Linh T. Nguyen United States	22	394 0.6×	317 0.7×	412 1.1×	77 0.7×	46 0.4×	71	1.3k
Prabhu Rajagopalan United States	17	360 0.6×	252 0.5×	365 1.0×	30 0.3×	84 0.8×	51	1.1k
Jiang Liu United States	16	446 0.7×	149 0.3×	426 1.1×	227 1.9×	162 1.5×	43	1.5k
Mirjam Crul Netherlands	18	447 0.7×	187 0.4×	490 1.3×	67 0.6×	41 0.4×	75	1.2k
Johanna N.H. Timmer-Bonte Netherlands	15	523 0.8×	212 0.5×	242 0.6×	43 0.4×	174 1.6×	38	910
Sakkaraiappan Ramalingam United States	12	334 0.5×	334 0.7×	376 1.0×	53 0.4×	39 0.4×	30	909
H. Diddens Germany	15	300 0.5×	339 0.7×	409 1.1×	33 0.3×	41 0.4×	38	1.0k
Naoko Imai Japan	18	956 1.5×	289 0.6×	304 0.8×	737 6.2×	119 1.1×	39	1.6k

Countries citing papers authored by Thomas Wehler

Since Specialization

Citations

This map shows the geographic impact of Thomas Wehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Wehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Wehler more than expected).

Fields of papers citing papers by Thomas Wehler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Wehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Wehler. The network helps show where Thomas Wehler may publish in the future.

Co-authorship network of co-authors of Thomas Wehler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Wehler. A scholar is included among the top collaborators of Thomas Wehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Wehler. Thomas Wehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grohé, Christian, Jan Stratmann, Stefan Hammerschmidt, et al.. (2025). 1904P Real-world outcomes of nintedanib plus docetaxel for adenocarcinoma NSCLC after failure of first-line immunochemotherapy: The non-interventional VARGADO study. Annals of Oncology. 36. S1018–S1019.

Aerts, Joachim G.J.V., Luis Paz‐Ares, Carole Hélissey, et al.. (2024). Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 2533–2533. 6 indexed citations

Bozorgmehr, Farastuk, Ursula Nestle, Fabian Weykamp, et al.. (2023). 1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial. Annals of Oncology. 34. S746–S746. 2 indexed citations

Bozorgmehr, Farastuk, Fabian Weykamp, Tobias R. Overbeck, et al.. (2023). 1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data. Annals of Oncology. 34. S1060–S1060. 7 indexed citations

Grohé, Christian, Thomas Wehler, Stefan Hammerschmidt, et al.. (2023). Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial.. Journal of Clinical Oncology. 41(16_suppl). e21149–e21149. 1 indexed citations

Wehler, Thomas, et al.. (2022). 1143P Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy. Annals of Oncology. 33. S1072–S1073. 2 indexed citations

Blettner, Maria, Kathy Taylor, Bernhard Gohrbandt, et al.. (2022). Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS. Journal of Cancer Research and Clinical Oncology. 148(8). 1943–1953. 2 indexed citations

Grohé, Christian, Werner J. Blau, Wolfgang Gleiber, et al.. (2022). Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study. Clinical Oncology. 34(7). 459–468. 13 indexed citations

Jabbour, Salma K., Baerin Houghton, Andrew Robinson, et al.. (2020). Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA Non–Small-Cell Lung Cancer (NSCLC): KEYNOTE-867. International Journal of Radiation Oncology*Biology*Physics. 108(3). e135–e136.

10.

Grohé, Christian, Wolfgang Gleiber, Siegfried Haas, et al.. (2020). 1372P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455). Annals of Oncology. 31. S875–S876. 1 indexed citations

11.

Shah, Rajiv, Laura V. Klotz, Manuel Feißt, et al.. (2020). 1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery. Annals of Oncology. 31. S1083–S1083. 1 indexed citations

12.

Viteri, Santiago, Julien Mazières, Rémi Veillon, et al.. (2020). 1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC. Annals of Oncology. 31. S831–S831. 6 indexed citations

13.

Hartmann, J. T., Hans‐Georg Kopp, Viktor Gruenwald, et al.. (2019). Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. European Journal of Cancer. 124. 152–160. 23 indexed citations

14.

Eichler, Martin, Marlene Hechtner, Roland Buhl, et al.. (2019). Use of psychosocial services by lung cancer survivors in Germany. Strahlentherapie und Onkologie. 195(11). 1018–1027. 7 indexed citations

15.

Hechtner, Marlene, Martin Eichler, Roland Buhl, et al.. (2018). Quality of Life in NSCLC Survivors — A Multicenter Cross-Sectional Study. Journal of Thoracic Oncology. 14(3). 420–435. 57 indexed citations

16.

Pföhler, Claudia, et al.. (2016). A Slowly Growing Orange Patch on the Cheek: Diagnosis of Lupus Vulgaris 20 Years After Onset of First Skin Changes. Dermatology and Therapy. 7(1). 181–185. 2 indexed citations

17.

Schmidtmann, Irene, Thomas Thomaidis, Peter R. Galle, et al.. (2016). Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World Journal of Gastroenterology. 22(23). 5400–5400. 7 indexed citations

18.

Hoffknecht, Petra, Amanda Tufman, Thomas Wehler, et al.. (2014). Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease. Journal of Thoracic Oncology. 10(1). 156–163. 217 indexed citations

19.

Wehler, Thomas, Yang Cao, Peter R. Galle, et al.. (2012). Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously. Oncology Letters. 3(6). 1191–1194. 7 indexed citations

20.

Wehler, Thomas, Annett Maderer, Claudine Graf, et al.. (2012). Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy. International Journal of Colorectal Disease. 28(3). 385–398. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact